Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
There is concern over whether or not patients are adhering to their treatment during the pandemic.
While there are many options available to treat type 2 diabetes, there is some concern over patient adherence during the coronavirus disease 2019 (COVID-19) pandemic.
With treatment adherence so important for diabetic patients, many doctors are concerned this patient population has not regularly taken or filled their prescriptions.
However, there are new treatments being explored that could really help these patients should they adhere to the prescribed doses.
During the 18th World Congress of Insulin Resistance Diabetes & Cardiovascular (WCIRDC) Online CME Conference presented by the Metabolic Institute of America (TMIOA), Kausik Ray, MD, a professor of Public Health at the School of Public Health of Imperial College London presented new data showing the benefits of bempedoic acid and PCSK9 siRNA (inclisiran).
Currently, bempedoic acid is currently approved in Europe and the US, making it the first cholesterol lowering oral agent approved in approximately 10 years.
However, inclisiran represents an entirely new class of drugs that targets a process called gene silencing. Ray expects this treatment to be available in both North America and Europe in 2021.
Ray explained in an interview with HCPLive®, how concerning the pandemic has been for diabetic patients and why the newer effective treatments could have a major impact on prescription patterns.